David Hobson

David has extensive patent drafting and multi-jurisdictional prosecution experience. He is also experienced at providing therapeutic freedom to operate and validity advice, as well as handling opposition proceedings before the EPO.  Some key hearings include: “Recombinant EPO” (Sterrenbeld Biotechnologie; Polymun Scientific Immunbiologische) and “Modified Clostridial Neurotoxins” (Ipsen Bioinnovation; Merz Pharma).

Building on his in-depth knowledge of biochemistry much of the patent work he performs relates to enzyme biotechnology, including its application in the food and pharmaceutical industries, as well as antibody therapeutics and plant biotechnology.

David has a PhD in Biochemistry from the Cancer Research UK London Research Institute (awarded by UCL).  His PhD was in the field of transcription and enzyme mechanisms, specifically. Click here for more information. 

David is a European Patent Attorney, Chartered UK Patent Attorney, EPI Member and a Fellow of the Chartered Institute of Patent Attorney

David has co-authored a number of publications and a link to these publications is below. 

The Nagoya Protocol – A Practical Overview, Thomas Bjørn & David Hobson, Copenhagen Life Science (September/October 2015)

When is it Health Data and When is it Not?, Thomas Bjørn & David Hobson, Copenhagen Life Science (July/August 2015)